VIDEO: ‘Remarkable’ triglyceride reduction observed with plozasiran
ATLANTA — In this Healio video exclusive, Erica S. Spatz, MD, MHS, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining studies aimed at reducing high triglycerides.
Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed one study that tested plozasiran, formerly ARO-APOC3 (Arrowhead Pharmaceuticals), on a population of patients with severe hypertriglyceridemia, which reduced their triglyceride levels at a “remarkable” rate, but also increased LDL levels.
“This drug is working as it should. Some of the other effects on the lipoproteins are interesting and maybe give some pause to whether or not this drug will ultimately move forward,” Spatz said.
Collapse
Read more about